4M Therapeutics

4M Therapeutics is a private, preclinical-stage biotech focused on central nervous system (CNS) disorders. Its core strategy involves using a human brain cell platform to discover and develop small molecules targeting neuroplasticity, neurogenesis, and neuroinflammation. The lead program, 4MT2001, is a GSK3β inhibitor positioned as a safer alternative to lithium for bipolar disorder, with a broader pipeline targeting agitation in Alzheimer's and neurodegeneration. The company is led by an experienced team with strong academic and industry backgrounds.

Living human brain cell platform using induced pluripotent stem cells (iPSCs) to screen and optimize drug candidates by examining effects on neuroplasticity, neurogenesis, and neuroinflammation pathways.

The CNS space is highly competitive with numerous large pharma and biotech companies. For bipolar disorder, 4MT2001 would compete against lithium, antipsychotics, and newer mechanisms. In Alzheimer's agitation, it would face competition from off-label antipsychotics and a few recently approved specialized drugs.